Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;Placebo
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-squamous Non-small-cell Lung Cancer
Conditions
Non-squamous Non-small-cell Lung Cancer
Trial Timeline
Feb 1, 2021 → Aug 16, 2025
NCT ID
NCT04619433About Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;Placebo
Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Non-squamous Non-small-cell Lung Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04619433. Target conditions include Non-squamous Non-small-cell Lung Cancer.
What happened to similar drugs?
3 of 20 similar drugs in Non-squamous Non-small-cell Lung Cancer were approved
Approved (3) Terminated (1) Active (16)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04619433 | Phase 3 | Terminated |
Competing Products
20 competing products in Non-squamous Non-small-cell Lung Cancer